Get the Stockscreener App
23.27
0.92%
-0.22
Sutro Biopharma Inc stock is traded at $23.27, with a volume of 14,062.
It is down -0.92% in the last 24 hours and up +13.73% over the past month.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
See More
Previous Close:
$23.50
Open:
$23.45
24h Volume:
14,062
Relative Volume:
0.09
Market Cap:
$381.37M
Revenue:
$105.65M
Net Income/Loss:
$-216.77M
P/E Ratio:
-1.3112
EPS:
-17.7511
Net Cash Flow:
$-225.11M
1W Performance:
+10.23%
1M Performance:
+13.73%
6M Performance:
+162.58%
1Y Performance:
+204.15%
1-Day Range:
$23.18
$24.18
1-Week Range:
$19.11
$26.34
52-Week Range:
$5.231
$26.54
Sutro Biopharma Inc Stock (STRO) Company Profile
Name
Sutro Biopharma Inc
Sector
Industry
Phone
650-392-8412
Address
111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Compare STRO vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
STRO
Sutro Biopharma Inc
|
23.18 | 386.56M | 105.65M | -216.77M | -225.11M | -17.75 |
VRTX
Vertex Pharmaceuticals Inc
|
451.39 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
754.55 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
329.82 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
687.64 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.26 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Sutro Biopharma Inc Stock (STRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-20-26 | Upgrade | Citizens JMP | Mkt Perform → Mkt Outperform |
| Jun-16-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-17-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-14-25 | Downgrade | BofA Securities | Buy → Underperform |
| Mar-14-25 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Mar-14-25 | Downgrade | Wedbush | Outperform → Neutral |
| May-08-24 | Initiated | BofA Securities | Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Buy |
| Oct-06-23 | Initiated | Oppenheimer | Outperform |
| Mar-21-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Aug-18-22 | Resumed | Wells Fargo | Overweight |
| Jun-18-21 | Initiated | H.C. Wainwright | Buy |
| Dec-03-20 | Initiated | Stifel | Buy |
| Sep-02-20 | Initiated | Jefferies | Buy |
| Jul-16-20 | Initiated | Wells Fargo | Overweight |
| Jan-13-20 | Initiated | SunTrust | Buy |
| Oct-07-19 | Initiated | BTIG Research | Buy |
| Jul-18-19 | Initiated | Deutsche Bank | Buy |
| Apr-29-19 | Initiated | H.C. Wainwright | Buy |
| Oct-22-18 | Initiated | JMP Securities | Mkt Outperform |
| Oct-22-18 | Initiated | Piper Jaffray | Overweight |
| Oct-22-18 | Initiated | Wedbush | Outperform |
View All
Sutro Biopharma Inc Stock (STRO) Latest News
Sutro Biopharma Inc buy Deutsche Bank Aktiengesellschaft - sharewise.com
Analyst James Shin Raises Price Target for Sutro Biopharma (STRO) to $55.00 | STRO Stock News - GuruFocus
Deutsche Bank Aktiengesellschaft Issues Positive Forecast for Sutro Biopharma (NASDAQ:STRO) Stock Price - MarketBeat
Deutsche Bank Adjusts Sutro Biopharma Price Target to $55 From $51, Maintains Buy Rating - marketscreener.com
HC Wainwright Predicts Sutro Biopharma FY2030 Earnings - MarketBeat
This Ralph Lauren Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday - Benzinga
Wells Fargo Upgrades Sutro Biopharma (STRO) with Significant Pri - GuruFocus
Sutro Biopharma (NASDAQ:STRO) Raised to "Overweight" at Wells Fargo & Company - MarketBeat
Sutro Biopharma (NASDAQ:STRO) Raised to Buy at HC Wainwright - MarketBeat
Wells Fargo Upgrades Sutro Biopharma to Overweight From Equal Weight, Adjusts PT to $27 From $8 - marketscreener.com
H.C. Wainwright upgrades Sutro Biopharma stock rating to buy By Investing.com - Investing.com Canada
Sutro's FY25 Net Loss Narrows; On Track To Report Initial Phase 1 Data Of STRO-004 In Mid-2026 - RTTNews
STRO Stock: HC Wainwright & Co. Upgrades Sutro Biopharma | STRO Stock News - GuruFocus
Sutro Biopharma (STRO) Receives Upgrade with Promising Outlook - GuruFocus
Sutro Biopharma Reports 2025 Financial Results, Advances Dual-Payload ADC Pipeline, and Extends Cash Runway to 2028 - Minichart
HC Wainwright & Co. upgrades Sutro Biopharma (STRO) - MSN
Sutro Biopharma Annual Report 2023: Business Overview, Risk Factors, and Financial Analysis - Minichart
Sutro Biopharma (NASDAQ: STRO) launches $100M ATM program with TD Cowen - Stock Titan
Sutro Biopharma Ends ATM Agreement After 2025 Results - TipRanks
Sutro Biopharma Reports Full Year 2025 Financial Results and Business Highlights - Bitget
Sutro Biopharma (NASDAQ:STRO) Issues Earnings Results - MarketBeat
Sutro Biopharma 2025 10-K: $102.5M revenue, $(22.49) EPS - TradingView
Sutro Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Sutro Biopharma (NASDAQ: STRO) expands ADC pipeline and monetizes partnerships - Stock Titan
Revenue jumps as Sutro Biopharma (NASDAQ: STRO) narrows 2025 loss - Stock Titan
Q4 financial results released by Sutro Biopharma with operational update - Traders Union
BRIEF-Sutro Biopharma FY Revenue USD 102.484 Million Vs. IBES Estimate USD 99.2 Million - TradingView
Sutro says cash lasts to 2028 as cancer drug pipeline advances - Stock Titan
Sutro Biopharma (STRO) 2024 Wells Fargo Healthcare Conference Summary - Quartr
If You Invested $1,000 in Sutro Biopharma (STRO) - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Analyst Upgrade: Is now the right time to enter Sutro Biopharma Inc2026 Summary & Community Consensus Trade Alerts - baoquankhu1.vn
Aug Action: What are Sutro Biopharma Inc.’s recent SEC filings showing2026 Retail Activity & AI Based Trade Execution Alerts - baoquankhu1.vn
Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Aug Rallies: Why is Allegro MicroSystems Inc. stock going down2026 Update & Accurate Trade Setup Notifications - baoquankhu1.vn
Sutro Biopharma, Inc. (NASDAQ:STRO) Short Interest Down 19.8% in February - MarketBeat
Sutro Biopharma: ADC Developer With Poor Track Record Aims For Positive 2026 (NASDAQ:STRO) - Seeking Alpha
Sutro Biopharma, Inc. to Present at 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026 - Quiver Quantitative
Fed Meeting: What is the Moat Score of Sutro Biopharma Inc2026 Retail & Daily Growth Stock Tips - baoquankhu1.vn
Sutro Biopharma (STRO) surges 11.9%: Is this an indication of further gains? - MSN
Sutro Biopharma Hits New 52-Week High of $25.68, Soars 556.88% - Markets Mojo
Sutro Biopharma Inc expected to post a loss of $4.34 a shareEarnings Preview - TradingView
Aug Swings: Can Sutro Biopharma Inc. continue delivering strong returns2026 Pullback Review & Safe Entry Momentum Stock Tips - baoquankhu1.vn
Sutro Biopharma Hits New 52-Week High of $21.40, Soars 453% - Markets Mojo
Sutro Biopharma (STRO) GC exercises RSUs as shares withheld for taxes - Stock Titan
Sutro Biopharma Hits New 52-Week High at $20.47, Soars 430% - Markets Mojo
Sutro Biopharma Hits New 52-Week High of $20.93, Up 431.69% - Markets Mojo
Sutro Biopharma Hits New 52-Week High of $20.48, Up 431.69% - Markets Mojo
Sutro Biopharma (STRO) to Release Quarterly Earnings on Thursday - MarketBeat
Sutro Biopharma: Transformed leadership and advanced ADC pipeline drive clinical progress, with key data due mid-year - TradingView
Sutro Biopharma: Transformed leadership and advanced ADC platform drive rapid clinical progress and innovation - TradingView
Sutro Biopharma Inc Stock (STRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Sutro Biopharma Inc Stock (STRO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Chung Jane | Chief Executive Officer |
Mar 04 '26 |
Option Exercise |
0.00 |
788 |
0 |
21,567 |
| Pauling David | Chief Admin. Ofcr. & GC |
Mar 02 '26 |
Option Exercise |
0.00 |
2,356 |
0 |
10,320 |
| Pauling David | Chief Admin. Ofcr. & GC |
Mar 01 '26 |
Option Exercise |
0.00 |
1,342 |
0 |
8,515 |
| Gerber Hans-Peter | CHIEF SCIENTIFIC OFFICER |
Mar 02 '26 |
Option Exercise |
0.00 |
2,843 |
0 |
10,688 |
| Gerber Hans-Peter | CHIEF SCIENTIFIC OFFICER |
Mar 01 '26 |
Option Exercise |
0.00 |
1,125 |
0 |
8,308 |
| Chung Jane | Chief Executive Officer |
Mar 02 '26 |
Option Exercise |
0.00 |
7,750 |
0 |
23,558 |
| Chung Jane | Chief Executive Officer |
Mar 01 '26 |
Option Exercise |
0.00 |
3,188 |
0 |
17,079 |
0.99%
3.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):